A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.

@article{Pidala2012ARP,
  title={A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.},
  author={Joseph A Pidala and Jongphil Kim and Heather S L Jim and Mohamed A Kharfan-Dabaja and Taiga Nishihori and Hugo F Fernandez and Marcie Riches Tomblyn and Lia Elena Perez and Janelle B Perkins and Mian Xu and William E Janssen and Anandaraman Veerapathran and Brian Betts and Frederick L Locke and Ernesto Ayala and Teresa L. Field and Leonel Ochoa and M. Sabes Alsina and Claudio Anasetti},
  journal={Haematologica},
  year={2012},
  volume={97 12},
  pages={
          1882-9
        }
}
BACKGROUND There is evidence suggesting that sirolimus, in combination with tacrolimus, is active in the prevention of graft-versus-host disease. Sirolimus-based immune suppression may suppress alloreactive T cells, while sparing the survival and function of regulatory T cells. DESIGN AND METHODS We conducted a randomized trial to compare the impact of sirolimus/tacrolimus against that of methotrexate/tacrolimus on the prevention of graft-versus-host disease and regulatory T-cell… CONTINUE READING
Highly Cited
This paper has 36 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Pathology of Graft vs. Host Disease

Springer International Publishing • 2019
View 5 Excerpts
Highly Influenced